Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial
在一项随机 II 期试验中,接受 CVac(一种黏蛋白 1 树突状细胞疗法)治疗的卵巢癌患者的无进展生存期和总生存期
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1186/s40425-016-0137-x
Gray, H J; Benigno, B; Berek, J; Chang, J; Mason, J; Mileshkin, L; Mitchell, P; Moradi, M; Recio, F O; Michener, C M; Secord, A Alvarez; Tchabo, N E; Chan, J K; Young, J; Kohrt, H; Gargosky, S E; Goh, J C
肿瘤
肿瘤免疫
树突状细胞
卵巢癌
细胞生物学
树突状细胞
免疫/内分泌